| [1] |
WANG Manli, CHEN Hui, DUAN Zhi, XU Qimei, LI Zhen.
A study on communication mechanism of lung cancer cells in tumor microenvironment mediated by pleckstrin-2/miR-196a signal axis
[J]. China Oncology, 2024, 34(7): 628-638.
|
| [2] |
QIAN Bin, CHEN Haiquan.
Important progress in surgical treatment of lung cancer in 2023
[J]. China Oncology, 2024, 34(4): 335-339.
|
| [3] |
LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan.
Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications
[J]. China Oncology, 2024, 34(4): 368-379.
|
| [4] |
JIANG Mengqi, HAN Yuchen, FU Xiaolong.
Research progress on H-E stained whole slide image analysis by artificial intelligence in lung cancer
[J]. China Oncology, 2024, 34(3): 306-315.
|
| [5] |
WANG Shanshan, YE Dingwei, YANG Li, CHENG Fan, YANG Tiejun, ZHANG Xiaoping, YU Zhixian, ZHANG Qingyun, YANG Yong.
Correlation of HER2 expression and clinicopathological characteristics in patients with urothelial carcinoma in China
[J]. China Oncology, 2024, 34(11): 1011-1019.
|
| [6] |
ZHANG Siwei, MA Ding, JIANG Yizhou, SHAO Zhimin.
“Subtype-precise” therapy leads diagnostic and therapeutic innovations: a new pattern for precision treatment of breast cancer
[J]. China Oncology, 2024, 34(11): 1045-1052.
|
| [7] |
ZHAO Junxiu, ZHU Yi, SONG Xiaoyu, ZHE Chao, XIAO Yuhan, LIU Yunduo, LI Linhai, XIAO Bin.
Circ-0007766 acts as a miR-1972 sponge to promote breast cancer cell migration and invasion via upregulation of HER2
[J]. China Oncology, 2024, 34(10): 915-930.
|
| [8] |
WU Han, YANG Zhangru, FENG Wen, ZENG Wanqin, GUO Jindong, LI Hongxuan, WANG Changlu, WANG Jiaming, LÜ Changxing, ZHANG Qin, YU Wen, CAI Xuwei, FU Xiaolong.
The efficacy and prognosis analysis after stereotactic body radiotherapy for multiple primary early-stage lung cancer
[J]. China Oncology, 2023, 33(9): 844-856.
|
| [9] |
ZHANG Lingling, WANG Xiangyi, WEI Xing, LIN Li, TANG Chuanhao, LIANG Jun.
A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis
[J]. China Oncology, 2023, 33(8): 776-781.
|
| [10] |
KANG Yinnan, CHEN Shun, XIE Youcheng, ZHENG Ying, HE Yujing, LI Chuyi, YU Xiaohui.
Application and research progress of antibody drug conjugates in HER2 positive advanced gastric cancer
[J]. China Oncology, 2023, 33(8): 790-800.
|
| [11] |
WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng.
Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study
[J]. China Oncology, 2023, 33(7): 686-692.
|
| [12] |
ZHANG Haoting, ZHENG Jing, FU Mengjiao, ZHOU Jianying.
Research progress on thyroid dysfunction induced by immunotherapy for lung cancer
[J]. China Oncology, 2023, 33(7): 701-706.
|
| [13] |
YANG Wenxiao, GUO Linwei, LING Hong, HU Xin.
Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy
[J]. China Oncology, 2023, 33(5): 484-498.
|
| [14] |
WU Jing, ZHOU Juan, SU Chunxia.
Advances in fatty acid metabolism reprogramming of lung cancer
[J]. China Oncology, 2023, 33(5): 517-526.
|
| [15] |
LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun.
The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy
[J]. China Oncology, 2023, 33(4): 377-387.
|
